Artificial intelligence stopped prostate cancer from spreading in an advanced patient

Artificial intelligence stopped prostate cancer from spreading in a patient with an advanced form of the disease, new research shows. An unnamed patient with tumours that had spread outside his prostate was given a combination of an experimental drug and an approved cancer medication. AI technology, known as CURATE.AI, was used to continuously assess how well the patient responded to the drugs, with the medications' doses being adjusted accordingly. These dose changes reduced cancer markers in his blood to the lowest levels they had ever been, with CT scans also revealing the patient's tumours had not spread further. Lead author Professor Dean Ho, from the National University of Singapore, said: 'The unique ability for CURATE.AI to rapidly identify the drug doses that result in the best possible treatment outcomes allows for optimised personalised medicine.